102 related articles for article (PubMed ID: 7527014)
1. Cyclic hexapeptide NK-2 antagonists.
Hölzemann G; Löw A; Harting J; Greiner HE
Int J Pept Protein Res; 1994 Aug; 44(2):105-11. PubMed ID: 7527014
[TBL] [Abstract][Full Text] [Related]
2. Influence of lipophilicity on the biological activity of cyclic pseudopeptide NK-2 receptor antagonists.
Quartara L; Fabbri G; Ricci R; Patacchini R; Pestellini V; Maggi CA; Pavone V; Giachetti A; Arcamone F
J Med Chem; 1994 Oct; 37(21):3630-8. PubMed ID: 7932590
[TBL] [Abstract][Full Text] [Related]
3. Solution conformation of c-[Gln-Trp-Phe-Gly-Leu-Met], a NK-2 tachykinin antagonist.
Amodeo P; Rovero P; Saviano G; Temussi PA
Int J Pept Protein Res; 1994 Dec; 44(6):556-61. PubMed ID: 7705977
[TBL] [Abstract][Full Text] [Related]
4. Affinity of R 396, an NK-2 tachykinin receptor antagonist, for NK-2 receptors in preparations from different species.
Maggi CA; Patacchini R; Astolfi M; Rovero P; Giachetti A; Van Giersbergen PL
Neuropeptides; 1992 Jun; 22(2):93-8. PubMed ID: 1328923
[TBL] [Abstract][Full Text] [Related]
5. Solution conformation of a cyclic neurokinin antagonist: a NMR and molecular dynamics study.
Zhang M; Quinn TP; Wong TC
Biopolymers; 1994 Sep; 34(9):1165-73. PubMed ID: 7948730
[TBL] [Abstract][Full Text] [Related]
6. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
7. Effect of non-peptide tachykinin NK(1) receptor antagonists on non-adrenergic, non-cholinergic neurogenic mucus secretion in ferret trachea.
Khawaja AM; Liu Y; Rogers DF
Eur J Pharmacol; 1999 Nov; 384(2-3):173-81. PubMed ID: 10611439
[TBL] [Abstract][Full Text] [Related]
8. Cyclic peptides as selective tachykinin antagonists.
Williams BJ; Curtis NR; McKnight AT; Maguire JJ; Young SC; Veber DF; Baker R
J Med Chem; 1993 Jan; 36(1):2-10. PubMed ID: 7678430
[TBL] [Abstract][Full Text] [Related]
9. Conformational study of cyclo[Gln-Trp-Phe-Gly-Leu-Met] as NK-2 antagonist by NMR and molecular dynamics.
Siahaan TJ; Lutz K
J Pharm Biomed Anal; 1994 Jan; 12(1):65-71. PubMed ID: 8161607
[TBL] [Abstract][Full Text] [Related]
10. MEN 10,573 and MEN 10,612, novel cyclic pseudopeptides which are potent tachykinin NK-2 receptor antagonists.
Maggi CA; Quartara L; Patacchini R; Giuliani S; Barbanti G; Turini D; Giachetti A
Regul Pept; 1993 Sep; 47(2):151-8. PubMed ID: 8234901
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.
Hirschmann R; Yao W; Cascieri MA; Strader CD; Maechler L; Cichy-Knight MA; Hynes J; van Rijn RD; Sprengeler PA; Smith AB
J Med Chem; 1996 Jun; 39(13):2441-8. PubMed ID: 8691440
[TBL] [Abstract][Full Text] [Related]
12. [3H][beta-Ala8]neurokinin A-(4-10): a novel, selective radioligand for the tachykinin NK2 receptor.
Goso C; Astolfi M; Parlani M; Manzini S
Eur J Pharmacol; 1995 Dec; 294(1):239-45. PubMed ID: 8788437
[TBL] [Abstract][Full Text] [Related]
13. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
Bellucci F; Meini S; Catalioto RM; Catalani C; Giuliani S; Quartara L; Giolitti A; Faiella A; Rotondaro L; Candenas ML; Pinto FM; Maggi CA
Eur J Pharmacol; 2004 Sep; 499(3):229-38. PubMed ID: 15381044
[TBL] [Abstract][Full Text] [Related]
15. Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.
Meini S; Bellucci F; Catalani C; Cucchi P; Patacchini R; Rotondaro L; Altamura M; Giuliani S; Giolitti A; Maggi CA
Eur J Pharmacol; 2004 Mar; 488(1-3):61-9. PubMed ID: 15044036
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity study of neurokinins: antagonists for the neurokinin-2 receptor.
Dion S; Rouissi N; Nantel F; Jukic D; Rhaleb NE; Tousignant C; Télémaque S; Drapeau G; Regoli D; Naline E
Pharmacology; 1990; 41(4):184-94. PubMed ID: 1964226
[TBL] [Abstract][Full Text] [Related]
17. Radioiodinated substance P, neurokinin A, and eledoisin bind predominantly in NK1 receptors in guinea pig lung.
Geraghty DP; Mussap CJ; Burcher E
Mol Pharmacol; 1992 Jan; 41(1):147-53. PubMed ID: 1370705
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
Meini S; Bellucci F; Catalani C; Cucchi P; Giolitti A; Santicioli P; Giuliani S
J Pharmacol Exp Ther; 2009 May; 329(2):486-95. PubMed ID: 19218528
[TBL] [Abstract][Full Text] [Related]
19. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor.
Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Ferrer C; Giolitti A; Guelfi M; Rotondaro L; Warner FJ; Maggi CA
J Pharmacol Exp Ther; 1999 Aug; 290(2):487-95. PubMed ID: 10411554
[TBL] [Abstract][Full Text] [Related]
20. Tachykinin receptors in the small intestine of the cane toad (Bufo marinus): a radioligand binding and functional study.
Burcher E; Warner FJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jun; 357(6):692-700. PubMed ID: 9686947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
